Exchange: NYSE
Industry: Pharmaceuticals & Biotechnology
Last Trade: 4:00 PM ET 4/5/2013
Last 10 Quotes:
What's This?
| Fiscal Q4 Ending 12/12 |
Fiscal Q3 Ending 09/12 |
Fiscal Q2 Ending 06/12 |
Fiscal Q1 Ending 03/12 |
Fiscal Q4 Ending 12/11 |
|
Sales/Revenue |
1,508,900 | 1,413,900 | 1,491,400 | 1,391,900 | 1,382,800 |
Cost of Goods Sold (COGS) incl. D&A |
222,400 | 222,000 | 235,000 | 227,400 | 182,000 |
COGS excluding D&A |
157,200 | 95,100 | 201,700 | 164,700 | 150,000 |
Depreciation & Amortization Expense |
65,200 | 126,900 | 33,300 | 62,700 | 32,000 |
Gross Income |
1,286,500 | 1,191,900 | 1,256,400 | 1,164,500 | 1,200,800 |
SG&A Expense |
790,100 | 834,000 | 816,500 | 810,100 | 775,100 |
Research & Development |
239,300 | 293,300 | 232,000 | 225,000 | 226,400 |
Other SG&A |
550,800 | 540,700 | 584,500 | 585,100 | 548,700 |
Other Operating Expense |
0 | 0 | 0 | 0 | 32,000 |
Unusual Expense |
85,200 | -3,200 | -3,400 | NA | 2,300 |
Non Operating Income/Expense |
51,000 | -16,300 | 500 | -15,000 | 9,000 |
Equity in Affiliates (Pretax) |
NA | 0 | 0 | 0 | 0 |
Interest Expense |
14,800 | 15,900 | 17,100 | 15,800 | 16,700 |
Gross Interest Expense |
15,700 | 15,900 | 17,100 | 15,800 | 16,700 |
Pretax Income |
449,300 | 330,800 | 428,400 | 324,800 | 383,700 |
Income Tax |
124,100 | 80,200 | 132,000 | 94,500 | 104,000 |
Equity in Affiliates |
0 | 0 | 0 | 0 | 0 |
Consolidated Net Income |
325,200 | 250,600 | 296,400 | 230,300 | 279,700 |
Minority Interest Expense |
1,000 | 1,200 | 1,000 | 500 | -100 |
Net Income |
324,200 | 249,400 | 295,400 | 229,800 | 279,800 |
Extraordinaries & Discontinued Operations |
0 | 0 | 0 | 0 | 0 |
Extra Items & Gain/Loss Sale Of Assets |
0 | 0 | 0 | 0 | 0 |
Cumulative Effect - Accounting Chg |
0 | 0 | 0 | 0 | 0 |
Discontinued Operations |
0 | 0 | 0 | NA | 0 |
Net Income After Extraordinaries |
324,200 | 249,400 | 295,400 | 229,800 | 279,800 |
Preferred Dividends |
0 | 0 | 0 | 0 | 0 |
Net Income available to Common |
324,200 | 249,400 | 295,400 | 229,800 | 279,800 |
Operational EPS |
1.25 | 0.81 | 0.95 | 0.74 | 0.91 |
EPS (basic) |
1.08 | 0.83 | 0.98 | 0.76 | 0.92 |
EBITDA |
561,600 | 484,800 | 473,200 | 417,100 | 425,700 |
Depreciation & Amortization Expense |
65,200 | 126,900 | 33,300 | 62,700 | 32,000 |
Common Shares Outstanding |
307,100 | 305,300 | 308,200 | 309,700 | 310,200 |
Basic Shares Outstanding |
301,500 | 300,100 | 302,400 | 303,900 | 304,400 |
Diluted Shares Outstanding |
307,100 | 305,300 | 308,200 | 309,700 | 310,200 |
Diluted EPS after Extraordinary Items |
1.06 | 0.82 | 0.96 | 0.74 | 0.90 |
Discont. Operations Per Share |
0 | 0 | 0 | 0 | 0 |
Continued operations EPS |
1.09 | 0.83 | 0.98 | 0.76 | 0.90 |
*Figures in thousands of U.S. Dollars except shares outstanding.
